StockNews.AI
RNXT
StockNews.AI
146 days

RenovoRx Pre-Clinical Results Supporting TAMP™ as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting

1. RenovoRx's TAMP therapy platform will be featured in a medical journal. 2. Recognition could enhance RNXT's credibility and attract investor interest.

2m saved
Insight
Article

FAQ

Why Bullish?

The publication in a respected journal boosts RenovoRx's credibility, similar to other biotech firms whose successful studies led to increased stock prices.

How important is it?

The publication's positive implication about TAMP effectiveness can spur short-term investment interest, impacting stock price.

Why Short Term?

Immediate recognition can enhance market perception and lead to short-term stock movement as investors react to news.

Related Companies

AVEOTGTXCLVS
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, is proud to announce that a publication supporting the Company's proprietary Trans-Arterial Micro-Perfusion (TAMP) therapy platform for targeted locoregional drug delivery will be recognized in the Journal of Vascular and Interventional Radiology (.

Related News